Leave Your Message
Nitroquinoline as an oral antibacterial drug for the treatment of urinary tract infections

Products

Nitroquinoline as an oral antibacterial drug for the treatment of urinary tract infections

Nitroxoline (5-nitroquinolin-8-ol) is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections.

    Product parameters

    Product Name

    Nitroxoline

    CAS NO

    4008-48-4

    Structure

    Nitroquinoline.jpg

    Molecular formula

    C9H6N2O3

    Purity

    Over 99.5%

    Other product names

    5-Nitro-8-quinolinol, 8-Hydroxy-5-nitroquinoline, 5-Nitro-8-hydroxyquinoline, 5-nitroquinolin-8-ol

    Molecular weight

    190.16

    In vitro activity

    Using spectrophotometric fluorescence assay, Nitroxoline can significantly reduce the degradation of extracellular DQ collagen IV in all tested cancer cell lines. Nitroxoline can significantly reduce real-time monitoring of tumor cell invasion and decrease the invasive growth of multicellular tumor spheroids, which can be used as a three-dimensional vitreous model of tumor invasion. In vitro angiogenesis experiments, Nitroxoline can significantly reduce the formation of endothelial tubes

    In vitro activity

    Nitroxoline significantly inhibited tumor growth,angiogenesis and metastasis in LPB fibrosarcoma and MMTV PyMT breast cancer mouse models.

    Kinase experiment

    In Vitro Kinase Assays : The potency of SP600125 towards kinases, including MPS1, JNK, and Aurora kinase A, is determined based on the specific measurement of radioactive phosphotransfer to the substrate. For each enzyme, the absolute Km values for ATP and the specific substrate are initially determined and each assay is then run at optimized [ATP] (2·αKm) and [substrate] (5·Km) concentrations. MPS1 activity is measured using 5 nM of MPS1 recombinant protein in 50 mM HEPES pH 7.5, 2.5 mM MgCl2, 1 mM MnCl2, 1 mM DTT, 3 μM NaVO3, 2 mM β-glycerophosphate, 0.2 mg/mL BSA, 200 μM P38-βtide substrate-peptide (KRQADEEMTGYVATRWYRAE), and 8 μM ATP with 1.5 nM 33P-γ-ATP. Ten serial 1:3 dilutions (from 30 μM to 1.5 nM) of SP600125 are tested and IC50 determined.
    DJI_0701gqj4H0A5610fa5

    Cell experiment

    Cell suspension are seeded in the wells of an E-plate 16 according to the manufacturer's instructions. After seeding, the CI is monitored every 15 min. After ∼10 h (MCF-10A neoT and MMTV-PyMT), 14 h (U-87 MG) or 24 h (LPB), when the cells are in their log phase of growth, 50 μl of the compound or 0.1% DMSO is added, and the experiment allowed to run for 72 h. Once every 24 h the medium is replaced with fresh medium containing the inhibitor or suitable control to prevent cell death due to medium depletion. Compounds and their concentrations are: nitroxoline (5 μM) and CA-074 (5 μM) for all cell lines other than MCF-10A neoT cell line, where nitroxoline was used at 2.5 μM. All measurements were performed in quadruplicate. (Only for Reference)

    Leave Your Message